Skip to main content
Top

Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don’t Know

Published in:

Abstract

Benzodiazepines, first introduced in the 1960s as effective and safer alternatives to barbiturate sedative-hypnotics, are now widely viewed as having a high risk of overdose, abuse, addiction, and “dependency”. These beliefs are contrary to extensive scientific evidence. Systematic research has shown that prescribed benzodiazepines are not prone to tolerance, dose-escalation, abuse, or addiction. Benzodiazepine abuse and overdose fatalities occur largely in the context of established polysubstance abuse. They are as effective as antidepressants and have fewer adverse effects but similar withdrawal syndromes. Major adverse effects are impairment of coordination, memory, and cognition, of most concern in older populations, and increased risk of motor vehicle accidents, especially when used along with alcohol. Most patients can be withdrawn from benzodiazepines without major difficulty using clinician supportiveness and flexible tapers. Reports of severe adverse reactions to benzodiazepines and of severe, prolonged difficulties withdrawing from them have not been subjects of systematic study and are poorly understood. In summary, the literature supports use of benzodiazepines on par with antidepressants for anxiety disorders, and for benzodiazepines and z-drugs for short-term mitigation of insomnia.
Title
Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don’t Know
Author
Edward K. Silberman
Publication date
01-12-2025
Publisher
Springer International Publishing
Published in
Drugs / Issue 1/2026
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-025-02261-2
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images